CHF 6333

Drug Profile

CHF 6333

Alternative Names: CHF-6333

Latest Information Update: 01 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Antibronchitics; Antifibrotics
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Bronchiectasis; Cystic fibrosis

Most Recent Events

  • 01 Nov 2016 Phase-I clinical trials in Cystic fibrosis (In volunteers) in Belgium (Inhalation) (NCT03056326)
  • 01 Nov 2016 Phase-I clinical trials in Bronchiectasis (In volunteers) in Belgium (Inhalation) (NCT03056326)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top